Menu

An expert resource for medical professionals
Provided FREE as a service to women’s health

The Alliance for
Global Women’s Medicine
A worldwide fellowship of health professionals working together to
promote, advocate for and enhance the Welfare of Women everywhere

An Educational Platform for FIGO

The Global Library of Women’s Medicine
Clinical guidance and resources

A vast range of expert online resources. A FREE and entirely CHARITABLE site to support women’s healthcare professionals

The Global Academy of Women’s Medicine
Teaching, research and Diplomates Association

This chapter should be cited as follows:
Dhillon Pai R, Kundnani MT, et al, Glob. libr. women's med.,
ISSN: 1756-2228; DOI 10.3843/GLOWM.421083

The Continuous Textbook of Women’s Medicine SeriesGynecology Module

Volume 15

Reproductive medicine for the obstetrician and gynecologist

Volume Editors: Professor Luca Gianaroli, S.I.S.Me.R. Reproductive Medicine Institute, Italy; Director of Global Educational Programs, IFFS
Professor Edgar Mocanu, RCSI Associate Professor in Reproductive Medicine and Surgery, Rotunda Hospital, Ireland; President, IFFS
Professor Linda Giudice, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, USA; Immediate Past President, IFFS

Published in association with the
International Federation of
Fertility Societies

Chapter

Artificial Insemination

First published: November 2024

Study Assessment Option

By completing 4 multiple-choice questions (randomly selected) after studying this chapter readers can qualify for Continuing Professional Development awards from FIGO plus a Study Completion Certificate from GLOWM
See end of chapter for details

INTRODUCTION

Artificial insemination means the introduction of a semen sample into the female reproductive tract for the purpose of accomplishing pregnancy through in vivo fertilization. The rationale behind the procedure is to increase the density of gametes at the site of fertilization. The procedure can either be done with the partner’s semen sample (homologous artificial insemination – AIH) or donor semen (AID) and is often offered as first line of treatment to many infertile couples worldwide and those seeking pregnancy who may not have a male partner. Artificial insemination can be done intravaginal, intracervical or intrauterine, amongst these intrauterine inseminations or IUI is the most commonly practiced worldwide and is discussed in detail in this chapter.

INTRAUTERINE INSEMINATION 

Intrauterine insemination (IUI) is a simple, easy and cost-effective assisted reproductive technique which involves introduction of a washed semen sample into the uterine cavity around the time of ovulation. The treatment requires minimal equipment, is easy to perform, is less invasive and is associated with less psychological and financial burden compared to in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI). The treatment is thus associated with good couple compliance and lower drop-out rates compared to other more complex assisted reproductive technologies (ART) treatments. Though the treatment was first described centuries ago, it gained popularity in 1980s. The past four decades have witnessed multiple researches evaluating different aspects of this treatment including indications, optimal ovarian stimulation, semen preparation techniques, ovulation trigger (choice of drug to achieve final oocyte maturation and trigger ovulation), timing and luteal phase support.

RATIONALE FOR INTRAUTERINE INSEMINATION

The rationale behind the procedure is to increase the quality and quantity of gametes at the site of fertilization, thereby increasing the probability of fertilization and achieving pregnancy. Additionally, the procedure helps to overcome sperm and cervical mucus abnormalities, if any.

INDICATIONS FOR INTRAUTERINE INSEMINATION

IUI with or without ovarian stimulation is widely advised for different infertility indications including male factor, unexplained infertility, cervical factor, and sexual disorders. Whether or not IUI is effective in these situations especially in relation to IVF/ICSI is debatable as there is lack of good quality randomized controlled trials and prospective studies evaluating the efficacy of IUI individually for these indications. Table 1 lists the common indications of IUI as used by different clinicians.1

1

Indications of IUI.

  • Mild male factor infertility
  • Unexplained Infertility
  • Ovulatory dysfunction/anovulation
  • Sexual disorders
  • Mild endometriosis (grade 1/2)
  • Cervical factors
  • Immunological factors
  • Chronic viral infections- HIV/HBsAg
  • Donor IUI – azoospermia, severe male factor not affording intracytoplasmic sperm injection (ICSI), single women, serodiscordant couples, lesbian couple

Male factor infertility – IUI is routinely advised for couples with mild (sperm count between 5 and 14 million sperm/ml) to moderate male factor (sperm count between 1 and 5 million sperm/ml) infertility.2,3 However, according to a Cochrane database systematic review of the evidence of the usefulness of IUI in mild to moderate male factor infertility is insufficient.4 However, a randomized controlled trial conducted by Bensdorp et al. showed that IUI with ovarian stimulation is not inferior to IVF in mild to moderate male factor infertility.5

Unexplained infertility – The effectiveness of IUI in women with unexplained infertility was analyzed by Veltman-Verhulst et al. in a Cochrane systematic review.6 They observed that IUI in natural cycle does not benefit women with unexplained infertility. However, IUI with ovarian stimulation can significantly improve the pregnancy rates in these women.

Cervical factor – The role of IUI with or without ovarian stimulation in women with cervical factor infertility is debatable. A systematic review by Helmerhorst et al. did not find IUI to be beneficial these women.7 Also, postcoital testing as a part of an infertility workup to diagnose cervical factor is now not recommended as it is subjective, poorly reproducible, inconvenient, rarely changes the clinical management; further discouraging the use of IUI for this indication.8,9

Sexual disorders – IUI is beneficial in sexual disorders like hypospadias, vaginismus, retrograde ejaculation and impotence. However, intravaginal or intracervical insemination can also be performed in such cases. In males with retrograde ejaculation, where the semen parameters are also compromised, IUI should be the preferred choice.

Prerequisites before IUI:

  • At least one patent Fallopian tube;
  • Good ovarian reserve:
  • Minimal semen parameters – total motile sperm count (TMSC) ≥5 million/ml or a total count of ≥10 million,10 motility >30%, morphology >4% normal forms.

Contraindications for IUI:

  • Bilateral tubal blockage;
  • Severe tubal damage;
  • Severe pelvic infection;
  • Poor egg reserve;
  • Severe male factor infertility (<1 million sperm/ml).

OVARIAN STIMULATION BEFORE INTRAUTERINE INSEMINATION

Controlled ovarian stimulation (COS) is known to have an independent positive effect on pregnancy rate when combined with IUI. A study by van Rumste et al. showed that, compared to monofollicular growth, pregnancy rates increase by 5, 8 and 8%, respectively, when two, three or four dominant follicles are present before IUI.11 Another study by Huttenten et al. showed that the highest pregnancy rates are seen with three preovulatory follicles.12 The risk of multiple pregnancy increases tenfold with four or more follicles with no further increase in pregnancy rates.

Different stimulation agents and protocols have been used for ovarian stimulation for IUI. These include oral agents (clomiphene citrate and letrozole), gonadotropins, and combination of oral agents and gonadotropins. Oral drugs (clomiphene citrate/letrozole) are economical, require less monitoring and are associated with a lower risk of ovarian hyperstimulation syndrome (OHSS) and, thus, seem to be most cost-effective. Gonadotropin protocols are shown to have highest success rates but are more expensive, require stringent monitoring, and are associated with higher incidences of OHSS and multiple pregnancy. Gonadotropin releasing hormone (GnRH) analogs have also been used in IUI cycles; however, these have not been found to be cost-effective and have not resulted in significant increases in pregnancy rates.13,14 However, a select group of patients with a history of premature LH surge or premature follicle rupture may benefit by addition of a GnRH antagonist in subsequent cycles.

A randomized controlled trial by Cohlen et al. compared IUI with or without ovarian stimulation (OS) in couples with male infertility.15 They observed that OS results in increased pregnancy rates only when TMSC is >10 million. No significant improvement in pregnancy rates was seen with OS when TMSC was <10 million. OS and IUI significantly increase live birth rates in women with unexplained infertility (Cochrane database systematic review).13

Ovarian stimulation should be mild and should aim to result in 2–3 dominant follicles. Strict ultrasound monitoring is mandatory for all cycles. All preventive measures should be taken to avoid multiple gestations. It is advisable to cancel the cycle or convert to IVF in case of 4 or more dominant follicles are present on the day of triggering ovulation.

Ovulation is triggered when one or two dominant follicles reach the size of 18 mm. Different drugs (human chorionic gonadotropin (hCG), recombinant hCG or GnRH agonists) can be used to trigger ovulation. In a randomized controlled trial by Le et al., it was observed that hCG trigger was associated with significantly higher clinical pregnancy rates compared to GnRH agonist trigger.16 As women undergoing IUI are at low risk of OHSS, hCG trigger should be more beneficial in terms of pregnancy outcomes.

TIMING OF INTRAUTERINE INSEMINATION

Oocytes and spermatozoa are known to survive for a limited time period. Therefore, appropriate timing of IUI seems to be essential.17 IUI can be timed according to the LH surge (in natural cycles) or according to the hCG trigger. Most clinicians prefer to do IUI just before or within 10 hours of ovulation. A randomized controlled trial by Blockeel et al. showed that IUI in natural cycles should be performed 1 day after detection of the LH surge.18

In hCG triggered IUI cycles, IUI is usually performed 36 hours after the trigger. However, no significant difference in ongoing pregnancy or live birth rates was observed when IUI was performed in different time frames between 20 and 48 hours after hCG trigger.19,20 It is thus concluded that undertaking IUI between 20 and 48 hours after hCG trigger does not compromise success rates.

SPERM PREPARATION TECHNIQUES

Different sperm preparation techniques are used for washing semen samples before IUI. The sperm preparation aims to separate viable sperm from non-viable sperm and other cells in the seminal fluid including epithelial cells and leucocytes. Also, the seminal plasma is known to have some decapacitating factors which need to be removed for complete capacitation of sperm.21 The ideal technique for sperm preparation should be simple, low-cost, safe and reliable, and can isolate the sperm with intact genetic and functional properties without causing DNA damage.22

The commonly used sperm preparation techniques are simple wash, swim-up and density gradient. Although the density gradient technique is shown to be superior to simple wash and swim up in terms of better postwash semen parameters (greater number of morphologically normal sperm with better motility), no significant difference in pregnancy rates is observed with any of the techniques. A Cochrane systematic review concluded that there is insufficient evidence to recommend any one technique of semen preparation over another in terms of clinical outcomes after IUI.23

Newer sperm preparation techniques, e.g., MACS (magnetic activated cell sorting) and microfluidics, are also being increasingly used for sperm preparation. MACS specifically separates apoptotic from non-apoptotic sperm. Microfluidic devices are apt for developing automated sperm preparation instruments. These devices avoid the harmful effects of centrifugation on sperm quality and sperm with better motility can be extracted. Although some studies have shown that these advanced sperm selection methods can improve ART outcomes, larger studies are needed to validate their efficacy in clinical practice.24

SEMEN PARAMETERS AND INTRAUTERINE INSEMINATION

Various semen parameters have been evaluated as prognostic factors for the success of IUI. These include inseminating motile count after washing (IMC), sperm morphology using strict criteria, total motile sperm count (TMSC) and sperm motility. However, a clear definition of pre- and post-wash sperm parameters below which IUI is no longer cost-efficient and should be withheld, is lacking. In a review by Ombelet et al., it was observed that inseminated motile count >1 million and morphology >4% normal forms are the cut offs below which IUI should be withheld.25 Another meta-analysis by Van Weert et al. suggested that inseminated motile count should at least be between 0.8 and 5 million for IUI to be performed with acceptable pregnancy rates.26 Various other researchers have reported a cut off value of 5–10 million and 30% for TMSC and TM, respectively.27,28 However, more prospective cohort studies are needed to find out the cut offs above which IUI can be recommended as first-line treatment.

SINGLE VERSUS DOUBLE INSEMINATION

The number of inseminations in one cycle is not well defined in terms of pregnancy rates. Theoretically, increasing the number of inseminations might increase the number of sperm present at the time of ovulation and this may increase the probability of fertilization and pregnancy. However, double inseminations have not been found to improve pregnancy rates in all IUI cycles.

A Cochrane database systematic review found that double inseminations can be beneficial in couples with unexplained and male factor infertility.9 Another systematic review by Zavos et al. found significant benefit of double IUI in male infertility.29 However, a systematic review by Polyzos et al. and a randomized control trial by Rahman et al. did not observe benefit of double insemination in couples with unexplained infertility.30,31 As the current evidence does not prove superiority of double IUI to single IUI in most cases, double IUI should be advised only when proven effective, as it increases the cost of treatment and psychological burden. More prospective cohort studies or randomized controlled trials for each indication separately can help to decide number of inseminations per cycle.

BED REST AFTER INTRAUTERINE INSEMINATION

It has been observed that sperm reach the Fallopian tube within 5–10 minutes after IUI.32 Thus, it can be assumed that resting in the supine position after the procedure may prevent losing a large fraction of inseminated sperm by ‘back flow’ and may improve treatment outcomes.

Randomized control trials conducted by Custers et al. and Salah et al. observed significant improvement in pregnancy rates after immobilization in the supine position (15 and 10 minutes, respectively) compared to immediate mobilization after IUI.33,34 In both studies after three cycles, pregnancy rates per couple were significantly higher in the immobilization group. However, a randomized controlled trial conducted by van Rijsvik et al. did not find any significant difference in pregnancy rates after immobilization for 15 minutes versus direct mobilization.35

LUTEAL PHASE SUPPORT AFTER INTRAUTERINE INSEMINATION

Whether luteal phase progesterone supplementation is needed in IUI cycles is still a matter of debate and there is no consensus. A systematic review and meta-analysis conducted by Green et al. observed that progesterone supplementation in the luteal phase after IUI is beneficial in women who underwent ovarian stimulation with gonadotropins.36 However, no benefit was observed in women undergoing natural cycle IUI or IUI with ovarian stimulation with clomiphene.

FACTORS AFFECTING INTRAUTERINE INSEMINATION SUCCESS

The results of IUI in terms of pregnancy rates per treatment cycle vary considerably in different studies. This is mainly due to variability in study populations, different etiologies of infertility, and different stimulation protocols. Different factors can influence the success after IUI treatment. Table 2 lists the positive predictive factors for IUI success.

Age of the female partner – Female age is the most important predictor of IUI success. A sharp decline in success is observed in women more than 40 years of age, mainly related to decrease in oocyte quality.37

Age of the male partner  The effect of male age on IUI success is not very clear. A study by Bellver et al. did not observe any impact of advancing paternal age on IUI outcomes.38 However, another study conducted by Mathieu et al. observed a decrease in pregnancy rates in men >35 years compared to men <30 years after controlling for maternal age, ovulatory status, duration of infertility, and presence of asthenozoospermia and/or teratozoospermia.39

Cause of infertility  Couples with unexplained infertility and mild male factor infertility, cervical factor or ovulatory dysfunctions have better success rates compared to those with endometriosis and tubal factor.40,41,42

Sperm parameters  Various sperm parameters have been evaluated for predicting success after IUI treatment. The most important are sperm morphology with a cut off of 4% and total motile sperm count in the ejaculate ≥10 million or inseminating motile count of 0.5–5 million. The success of IUI treatment is very limited below these thresholds (see above).

Ovarian stimulation  Controlled ovarian stimulation (COS) plus IUI is known to give better success rates than IUI in a natural cycle. Ovarian stimulation with gonadotropins gives better success rates compared to COS with oral agents, although it increases the risk of multiple pregnancy.14

Time interval to semen collection to insemination  It has been observed that IUI performed within 90 minutes of semen collection gives better results compared to late insemination.43

Pre-washing the catheter with culture medium seems to increase the success rates per cycle.44

2

Positive predictive factors for IUI success.

  • Age of female partner <35 years
  • Duration of infertility <5 years
  • At least one patent normal fallopian tube with no uterine factor
  • Adequate ovarian reserve
  • Mild male factor

COMPLICATIONS 

The complications which can be encountered during IUI treatment include:

  • Ovarian hyperstimulation – mild stimulation with strict monitoring should be done to avoid OHSS;
  • Pain – improper processing of semen sample can release prostaglandins causing pain;
  • Trauma and bleeding – gentle atraumatic technique should be used;
  • Vasovagal syncope – rare;
  • Accidental mismatch of sample – this can be avoided by proper labeling of containers and all disposables, and by processing one sample at a time.

HOW MANY CYCLES OF INTRAUTERINE INSEMINATION?

There is no clear-cut guideline as to how many cycles of IUI should be offered to a couple undergoing fertility treatment. A common practice amongst clinicians worldwide is to offer 3–6 cycles of IUI before pursuing other treatment approaches. Bensdorp et al. in a randomized controlled trial concluded that it is cost-effective to offer 6 cycles of OS-IUI in couples with unexplained infertility or mild male factor infertility compared to going directly to IVF.5 A prospective study by Aboulghar et al. in women with unexplained infertility showed that clinical pregnancy rates were significantly higher in the first 3 cycles compared to next 3 cycles. Based on this observation, they suggested that at least 3 cycles of IUI should be offered.45 However, there is insufficient evidence to recommend a maximum number of cycles.

FALLOPIAN SPERM PERFUSION

Fallopian sperm perfusion (FSP) involves insemination of larger volume of semen sample (4 ml) into the uterine cavity transcervically compared to 0.5 ml in regular IUI. FSP aims to flush the tubes with sperm and to have a increased number of spermatozoa in the tube around the time of ovulation. However, a Cochrane systematic review by Cantineau et al. did not show benefit of FSP compared to IUI in terms of live birth rates, thus IUI is recommended as the treatment of choice.46

CONCLUSION

Artificial insemination is a valuable first line of treatment for many infertile couples. It is a simple, non-invasive yet cost-effective technique which requires minimal expertise and infrastructure. COS-IUI has better pregnancy rates compared to natural cycle IUI. However, ovarian stimulation should be mild and all precautions should be taken to avoid multiple gestation. Inseminating motile count >1 million, morphology >4% normal forms are good predictors for IUI success. IUI can be performed within 20–48 hours of hCG trigger. Double inseminations can be beneficial in case of male factor infertility. Immobilization for 10–15 minutes after IUI improves the success rates.

PRACTICE RECOMMENDATIONS

IUI Recommendations47

  • Controlled ovarian hyperstimulation is known to have an independent positive effect on pregnancy rate when combined with IUI.
  • There are no clear cut off levels of pre- or post-wash semen parameters below which IUI should be withheld.
  • Total motile sperm count (TMSC) >10 million, morphology >4% normal forms are good predictors of IUI success.
  • IUI can be performed anytime between 24 and 40 hours after hCG trigger.
  • IUI in natural cycles should be performed 1 day after detection of LH surge.
  • The available evidence is insufficient to recommend any one semen preparation technique over another.
  • Double insemination is not recommended except in male factor.
  • Women undergoing IUI should have 10–15 min of bed rest after the procedure.
  • Progesterone supplementation in luteal phase after IUI is beneficial in women who underwent ovarian stimulation with gonadotropins.
  • Fallopian sperm perfusion has no benefit over IUI and is not recommended.


CONFLICTS OF INTEREST

The author(s) of this chapter declare that they have no interests that conflict with the contents of the chapter.

REFERENCES

1

ESHRE Capri Workshop Group. Intrauterine insemination. Hum Reprod Update 2009;15:265–77.

2

Shaw W, Padubidri V, Daftary S, Howkins J, Bourne G. Infertility and sterility. In: Shaw’s Textbook of Gynecology, 16th edn. Elsevier, 2015:237-62.

3

Choy JT, Amory JK . Non surgical management of oligozoospermia. J Clin Endocrinol Metab 2020 Dec; 105(12): e4194–e4207. G.

4

Bensdorp AJ, Cohlen BJ, Heineman MJ, et al. Intra-uterine insemination for male subfertility. Cochrane Database Syst Rev 2007:CD000360. doi: 10.1002/14651858.CD000360.pub3.

5

Bensdorp AJ, Tjon-Kon-Fat RI, Bossuyt PMM, et al. Prevention of multiple pregnancies in couples with unexplained or mild male subfertility: randomised controlled trial of in vitro fertilisation with single embryo transfer or in vitro fertilisation in modified natural cycle compared with intrauterine insemination. Br Med J 2015;350:7771.

6

Veltman-Verhulst SM, Cohlen BJ, Hughes E, et al. Intra-uterine insemin- ation for unexplained subfertility. Cochrane Database Syst Rev 2012;9:CD001838.

7

Helmerhorst FM, Van Vliet HAAM, Gornas T, et al. Intra- uterine insemination versus timed intercourse for cervical hostility in subfertile couples. Cochrane Database Syst Rev 2005:CD002809. doi: 10.1002/14651858. CD002809.pub2.

8

Griffith CS. Grimes DA. The validity of postcoital test. Am J Obstet Gynecol 1990;162:615–20.

9

Oei SG, Helmerhorst FM, Bloemenkamp KW, et al. Effectiveness of the post coital test- randomised controlled trial. BMJ 1998;317:502–5.

10

RP Dickey RP,Pyrzak R, Lu PY, Taylor SN, Rye PH. Comparison of the sperm quality necessary for successful intrauterine insemination with WHO threshold values for normal sperm. Fertil Steril 1999 Apr,71(4):684-9.

11

van Rumste MME, Custers IM, van der Veen F, et al. The influence of the number of follicles on pregnancy rates in intrauterine insemination with ovarian stimulation: a meta-analysis. Hum Reprod Update 2008;14:563–70.

12

Nuojua-Huttunen S, Tomas C, Bloigu R, et al. Intrauterine insemination treatment in subfertility: an analysis of factors affecting outcome. Hum Reprod 1999;14(3):698–703.

13

Cantineau AEP, Cohlen BJ, Heineman MJ. Ovarian stimulation protocols (anti-oes- trogens, gonadotrophins with and without GnRH agonists/antagonists) for intra- uterine insemination (IUI) in women with subfertility. Cochrane Database Syst Rev 2007:CD005356. doi: 10.1002/14651858.CD005356.pub2.

14

Cantineau AEP, Cohlen BJ, Klip H, et al. The addition of GnRH antagonists in intrauterine insemination cycles with mild ovarian hyperstimulation does not increase live birth rates- a randomised, double blinded, placebo controlled trial. Hum Reprod 2011:26,1104–11.

15

Cohlen BJ, te Velde ER, van Kooij RJ, et al. Controlled ovar- ian hyperstimulation and intrauterine insemination for treating male subfertility: a controlled study. Hum Reprod 1998;13:1553–8.

16

Le TM, Nguyen Nguyen D, Zolton J, et al. GnRH Agonist versus hCG Trigger in Ovulation Induction with Intrauterine Insemination: A Randomized Controlled Trial. Int J Endocrinol 2019;2019:2487067.

17

Rahman SM, Karmakar D, Malhotra N, et al. Timing of intrauterine insemination: an attempt to unravel the enigma. Arch Gynecol Obstet 2011;284:1023–7.

18

Blockeel C, Knez J, Polyzos NP, et al. Should an intrauterine insemination with donor semen be performed 1 or 2 days after the spontaneous LH rise? A prospective RCT. Hum Reprod 2014;29:697–703.

19

Claman P, Wilkie V, Collins D. Timing intrauterine insemination either 33 or 39 hours after administration of human chorionic gonadotropin yields the same pregnancy rates as after superovulation therapy. Fertil Steril 2004;82:13–6.

20

AboulGheit S. Pregnancy rates following three different timings of intrauterine insemination for women with unexplained infertility: a randomised controlled trial. Middle East Fertil Soc J 2010;15:265–8.

21

Mortimer D. Sperm preparation methods. J Androl 2000;21:357–66.
.

22

World Health Organization WHO Laboratory Manual for the Examination and Processing of Human Semen, 5th edn. Geneva: World Health Organization, 2010.

23

Boomsma CM, Heineman MJ, Cohlen BJ, et al. Semen preparation techniques for intrauterine insemination. Cochrane Database Syst Rev 2007:CD004507. doi:.

24

Lepine S, McDowell S, Searle LM, et al. Advanced sperm selection techniques for assisted reproduction. Cochrane Database Syst Rev 2019;7(7):CD010461.

25

Ombelet W, Dhont N, Thijssen A, et al. Semen quality and prediction of IUI success in male subfertility: a systematic review. Reprod Biomed Online 2014;28:300–9.

26

van Weert J-M, Repping S, Van Voorhis BJ, et al. Performance of the postwash total motile sperm count as a predictor of pregnancy at the time of intrauterine insemination: a meta-analysis. Fertil Steril 2004;82:612–20.

27

Ombelet W, Vandeput H, Van de Putte G, et al. Intrauterine insemination after ovarian stimulation with clomiphene citrate: predictive potential of inseminating motile count and sperm morphology? Hum Reprod 1997;12:1458–63.

28

Van Waart J, Kruger TF, Lombard CJ, et al. Predictive value of normal sperm morphology in intrauterine insemination (IUI): a structured literature review. Hum Reprod 2001;7:495–500.

29

Zavos A, Daponte A, Garas A, et al. Double versus single homologous intrauterine insemination for male factor infertility: a systematic review and meta-analysis. Asian J Androl 2013;15:533–8.

30

Polyzos NP, Tzioras S, Mauri D, et al. Double versus single intrauterine insemination for unexplained infertility: a meta-analysis of randomized trials. Fertil Steril 2010;94:1261–6.

31

Rahman SM, Malhotra N, Kumar S, et al. A randomized controlled trial comparing the effectiveness of single versus double intrauterine insemination in unexplained infertility. Fertil Steril 2010;94:2913–5.

32

Suarez SS, Pacey AA. Sperm transport in the female reproductive tract. Hum Reprod Update 2006;12:23–37.

33

Custers IM, Flierman PA, Maas P, et al. Immobilisation versus immediate mobilisation after intrauterine insemination: randomised controlled trial. Br Med J 2009;339:b4080.

34

Saleh A, Tan SL, Biljan MM, et al. A randomized study of the effect of 10 minutes of bed rest after intrauterine insemination. Fertil Steril 2000;74:509–11.

35

van Rijswijk J, Caanen MR, Mijatovic V, et al. Immobilization or mobilization after IUI: an RCT. Hum Reprod 2017;32:2218–24.

36

Green KA, Zolton JR, Schermerhorn S, et al. progesterone luteal support after ovulation induction and intrauterine insemination: An updated systematic review and meta-analysis. Fertil Steril 2017;107:924–33.

37

Yarde F, Broekmans FJM. Factors influencing IUI outcome: female age. In: Cohlen BJ, Ombelet W (eds.) Intra-Uterine Insemination: Evidence-Based Guidelines for Daily Practice. Boca Raton, USA: CRC Press, Taylor & Francis Group, 2014:27–33.

38

Bellver J, Garrido N, Remohí J, et al. Influence of paternal age on assisted reproduction outcome. Reproductive BioMedicine Online 2008;17:595–604.

39

Mathieu C, Ecochard R, Bied V, et al. Cumulative conception rate following intrauterine artificial insemination with husband’s spermatozoa: influence of husband’s age. Hum Reprod 1995;10:1090–7.

40

Sahakyan M, Harlow BL, Hornstein MD. Influence of age, diagnosis, and cycle number on pregnancy rates with gonadotropin-induced controlled ovarian hyperstimulation and intrauterine insemination. Fertil Steril 1999;72:500–4.

41

Merviel P, Heraud MH, Grenier N, et al. Predictive factors for pregnancy after intrauterine insemination (IUI): An analysis of 1038 cycles and a review of the literature. Fertil Steril 2010;93:79–88.

42

Dickey RP, Taylor SN, Lu PY, et al. Effect of diagnosis, age, sperm quality, and number of preovulatory follicles on the outcome of multiple cycles of clomiphene citrate-intrauterine insemination. Fertil Steril 2002;78:1088–95.

43

Fauque P, Lehert P, Lamotte M, et al. clinical success of intrauterine insemination cycles is affected by the sperm preparation time. Fertil Steril 2014;6:1618:23.

44

Pont JC, Patrat C, Fauque P, et al. Pre-washing Catheter dramatically improves the post intrauterine insemination pregnancy rate. Gynecol Obstet Fertil 2012;40:356–9.

45

Aboulghar M, Mansour R, Serour G, et al. Controlled ovarian hyperstimulation and intrauterine insemination for treatment of unexplained infertility should be limited to a maximum of three trials. Fertil Steril 2001;75:88–91.

46

Cantineau AEP, Cohlen BJ, Heineman MJ, et al. Intrauterine insemination versus fallopian tube sperm perfusion for non-tubal infertility. Cochrane Database Syst Rev 2013;10:CD001502.

47

Cohlen B, Bijjerk A, Van Der Poel S, et al. IUI: review and systematic assessment of the evidence that supports global recommendations. Hum Reprod Update 2018;24:300–19.

Online Study Assessment Option
All readers who are qualified doctors or allied medical professionals can now automatically receive 2 Continuing Professional Development credits from FIGO plus a Study Completion Certificate from GLOWM for successfully answering 4 multiple choice questions (randomly selected) based on the study of this chapter.
Medical students can receive the Study Completion Certificate only.

 

(To find out more about FIGO’s Continuing Professional Development awards programme CLICK HERE)